Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2 month improvement in median progression-free survival (16.8 months compared to 5.6 months on placebo)
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).
Study reveals prolonging treatment with Brilinta 60mg after one year, reduces risk of major adverse cardiac events (MACE) by 19% and coronary death by 36%1 Builds on analysis2 showing 5-year ischaemic risk post-heart attack and benefits of long-term cardiovascular (CV) protection with Brilinta 60mg
Positiv utveckling avseende kommersiellt genomförande och kostnadsdisciplin; produktförsäljningen ökade under kvartalet. AstraZeneca står inför tillväxt i produktförsäljningen för helåret 2018
AstraZeneca today announced top-line results from the Phase III KRONOS trial that showed PT010 (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6µg, using Aerosphere Delivery Technology, in a pressurised metered-dose inhaler or pMDI) demonstrated a statistically significant improvement compared with dual combination therapies in six out of seven lung function primary endpoints.
AstraZeneca ranked 34th in Corporate Knights’ 14th annual Global 100 list of the most sustainable companies in the world
AstraZeneca identified as “biggest achiever” alongside Bank of America, and Coca Cola Enterprises Inc. (now Coca Cola European Partners) for 300% increase in renewable electricity in a single year
AstraZeneca has been recognised for its commitment to sustainability with tw
Lynparza is the first PARP inhibitor approved in Japan
Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare has approved Lynparza
Approval based on Phase III WINDWARD programme that demonstrated significant reductions in asthma exacerbations, improvements in lung functionand reductions inoral corticosteroid use from baseline, versus placebo
Fasenra is the first approved respiratory biologic with an 8-week maintenance dosing schedule
AstraZeneca and its global biologics research and development arm, MedImmune, today ann
AstraZeneca announced today the publication of a new analysis from an ongoing real-world quality registry that suggests the risk of experiencing a repeat heart attack (also known as a myocardial infarction or MI) from occlusions in non-stentedarteries is twice as high as the risk stemming from the initially stented artery following a first heart attack.
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm),
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Commission (EC) has approved Fasenra (benralizumab) as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists.
Acceptance follows FDA Breakthrough Therapy Designation
Tagrisso granted Priority Review
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for the use of Tagrisso (osimertinib), a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with clinical activity agains
AstraZeneca, along with Acerta Pharma, its haematology research and development centre of excellence, and MedImmune, its global biologics research and development arm, will highlight significant progress in blood cancer research at the 59th 2017 American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA
AstraZeneca today announced positive top-line results of the Phase IV ASCENT trial for Tudorza Pressair (aclidinium bromide 400 μg, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.
AstraZeneca today announced that the European Medicines Agency has accepted a variation to the Marketing Authorisation Application (MAAv) for Tagrisso (osimertinib),
AstraZeneca today announced a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China to discover, develop and commercialise potential new medicines to help meet unmet needs globally, and to bring innovative new medicines to patients in China faster.
AstraZeneca today announced the submission of a supplemental new drug application (sNDA) to Japan’s Pharmaceuticals and Medical Devices Agency for the use of Tagrisso (osimertinib).
Faslodex in combination with abemaciclib showed 16.4 months of progression-free survival (PFS)
Second approval in three months expands treatment options for women with HR+, HER2- advanced breast cancer
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a new indication for
Faslodex (fulvestrant), expanding the indication to include use with abemac
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Benralizumab riktar sig mot och avlägsnar snabbt eosinofiler och är det första biologiska läkemedlet för sjukdomar i andningsvägarna med en 8-veckorsdosering för underhållsbehandling
Rekommendationen är baserad på omfattande fas III-program som uppvisar betydande minskningar av astmaanfall, förbättrad lungfunktionoch minskad användning av orala steroider
AstraZeneca och MedImmune, bolagets g